Abstract
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Current Cancer Therapy Reviews
Title: Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Volume: 8 Issue: 1
Author(s): Cherie H. Dunphy
Affiliation:
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Abstract: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Export Options
About this article
Cite this article as:
H. Dunphy Cherie, Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462503
DOI https://dx.doi.org/10.2174/157339412799462503 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Functions of Polo-Like Kinases and their Relevance to Human Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Differential Role of Apoptosis and Autophagy Associated with Anticancer Effect of Lupulone (Hop β-Acid) Derivatives on Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Current Drug Targets The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Phytochemical Profiles, Antioxidant and Antibacterial Activities of 11 Phellinus Mushrooms Collected in Thailand
The Natural Products Journal Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets To Be, or Not To Be: That is the Question-Lineage Commitment in Hematopoiesis
Current Immunology Reviews (Discontinued) Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety Quantitative Structure-Activity Relationships for Anticancer Activity of 2- Phenylindoles Using Mathematical Molecular Descriptors
Current Computer-Aided Drug Design Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Liver Stem Cells and Possible Clinical Applications
Current Stem Cell Research & Therapy A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets